Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 1/20 | 0.50 |
| ▸ | LIPC | P11150 | 1/20 | 0.50 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.50 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | GRIK1 | P39086 | 3/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.46 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.46 |
| ▸ | SORT1 | Q99523 | 7/20 | 0.45 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MPO | P05164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2080677 | 0.83 | CCR2 (0.50) | PLK1LIPCLIPGKDM1AKDM4E | |
| SCHEMBL5127442 | 0.81 | LIPC (0.53) | PLK1LIPCLIPGKDM1AKDM4E | |
| SCHEMBL3886155 | 0.81 | KIF11 (0.56) | PLK1LIPCLIPGKDM1AKDM4E | |
| SCHEMBL3885198 | 0.81 | KDM4E (0.59) | PLK1LIPCLIPGKDM1AKDM4E | |
| SCHEMBL3897253 | 0.80 | PLK1 (0.50) | PLK1LIPCLIPGKDM1AKDM4E | |
| SCHEMBL2994470 | 0.80 | LIPC (0.55) | PLK1LIPCLIPGKDM1AKDM4E | |
| SCHEMBL2998300 | 0.80 | PLK1 (0.49) | PLK1LIPCLIPGKDM1AKDM4E | |
| SCHEMBL17627407 | 0.79 | LIPC (0.60) | PLK1LIPCLIPGKDM1AKDM4E | |
| SCHEMBL2987828 | 0.78 | LIPC (0.59) | PLK1LIPCLIPGKDM1AKDM4E | |
| SCHEMBL686710 | 0.78 | PLK1 (0.56) | PLK1LIPCLIPGKDM1AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021525-A1 | P70S6 Kinase Modulators and Method of Use | EXELIXIS, INC. (US) | 2011-01-27 | — | — | US | disclosed |
| US-7816353-B2 | P70S6 kinase modulators and method of use | EXELIXIS, INC. (US) | 2010-10-19 | — | — | US | disclosed |
| US-20070208020-A1 | P70S6 Kinase Modulators And Method Of Use | EXELIXIS, INC. | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021525-A1 | P70S6 Kinase Modulators and Method of Use | EEF2K, RPS6KA3, MTOR | PLK1 287/4885LIPC 3332/4885LIPG 910/4885 |
| US-20070208020-A1 | P70S6 Kinase Modulators And Method Of Use | EEF2K, RPS6KA3, MTOR | PLK1 287/4885LIPC 3332/4885LIPG 910/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.